Advances in platinum-intercalators of DNA as antitumor agents
10.11665/j.issn.1000-5048.20190501
- VernacularTitle:含DNA嵌入基团的抗肿瘤铂类配合物研究进展
- Author:
Tianshuai WANG
1
;
Junjie YU
;
Yan ZHANG
;
Jinjin ZENG
;
Jingxin CUI
Author Information
1. 湖北医药学院药学院；武当特色研究湖北省重点实验室
- Publication Type:Journal Article
- Keywords:
platinum complex;
antitumor agent;
DNA intercalators;
research progress
- From:
Journal of China Pharmaceutical University
2019;50(5):505-515
- CountryChina
- Language:Chinese
-
Abstract:
Platinum antitumor drugs are widely used for clinical treatment because of their unique antitumor mechanisms, significant antitumor effects, and broad antitumor spectrum. Yet shortcomings such as toxic side effects, drug resistance and cross-resistance of platinum-based drugs have limited their further application. Platinum-intercalator conjugates possess different antitumor mechanisms from those of classic platinum drugs, and have unique advantages in overcoming the disadvantages of classic platinum antitumor drugs. The platinum-intercalator conjugates can be classified into six categories based on the different DNA-intercalator: platinum-acridine, platinum-quinoline, platinum-indole, platinum-naphthalimides, platinum-anthraquinone and platinum-based antitumor agents containing other types of intercalating groups. This article summarizes the research progress of platinum-based antitumor drugs containing DNA insertion groups in recent years.
